Several groups, including ours, have focused on the therapeutic potential of DNMT inhibitors in the treatment of solid tumors with exciting early possibilities seen in non-small cell lung cancer (NSCLC) [3] and reversal of chemotherapy resistance in ovarian cancers [4]. This evidence concerns the gene DNMT1 and ovarian cancer.